NCT05022901View on ClinicalTrials.gov

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 10, 2022

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2024

Conditions
Metastatic Ocular MelanomaMetastatic Uveal Melanoma
Interventions
COMBINATION_PRODUCT

Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)

Melphalan administered directly to the liver via the Hepatic Delivery System (HDS) infused over a 30 minute period, followed by a 30 minute washout period

Trial Locations (5)

12902

Moffitt Cancer Center, Tampa

27710

Duke University Medical Center, Durham

38163

University of Tennessee Health Science Center, Memphis

43221

The Ohio State University, Columbus

94304

Stanford Cancer Institute, Palo Alto

All Listed Sponsors
lead

Delcath Systems Inc.

INDUSTRY